基本信息:
- 专利标题： C-SRC SELECTED REACTION MONITORING ASSAY
- 专利标题（中）：C-SRC选择的反应监测测定
- 申请号：PCT/US2011/045960 申请日：2011-07-29
- 公开(公告)号：WO2012016182A1 公开(公告)日：2012-02-02
- 发明人： KRIZMAN, David, B.
- 申请人： EXPRESSION PATHOLOGY, INC. , KRIZMAN, David, B.
- 申请人地址： 9620 Medical Center Drive, Suite 100 Rockville, MD 20850 US
- 专利权人： EXPRESSION PATHOLOGY, INC.,KRIZMAN, David, B.
- 当前专利权人： EXPRESSION PATHOLOGY, INC.,KRIZMAN, David, B.
- 当前专利权人地址： 9620 Medical Center Drive, Suite 100 Rockville, MD 20850 US
- 代理机构： BOOTH, Paul, M.
- 优先权： US61/369,411 20100730
- 主分类号： G01N33/483
- IPC分类号： G01N33/483 ; G01N30/72
摘要：
Objective quantitation of the c-Src protein directly in cancer patient tissue can aid in determining die aggressiveness of an individual patient's tumor as well as help make more informed decisions about choice of therapy. However, fee c-Src protein is currently analyzed directly in formalin fixed patient tissue only by immunohistoehemistry methodology which is at best subjectively semi-quantitative. This invention describes an objective quantitative assay for the c-Sre protein using mass spectrometry as the analytical methodology, Specific peptides, experimentally discovered characteristics about the peptides, and experimentally established assay conditions based on those peptide characteristics are provided for use in a mass speetronieiry-based Selected Reaction Monitoring (SRM) assay in order to measure relative- or absolute quantitative levels of c-Src directly in a protein preparation obtained from a formalin fixed cancer patient tissue sample.
摘要（中）：
c-Src蛋白直接在癌症患者组织中的客观定量可以帮助确定个体患者肿瘤的侵袭性，并帮助对治疗选择作出更明智的决定。 然而，费用c-Src蛋白质目前仅在福尔马林固定患者组织中通过免疫组织化学方法进行直接分析，该方法最多在主观上半定量。 本发明描述了使用质谱法作为分析方法的c-Sre蛋白质的客观定量测定法，特异性肽，关于肽的实验发现的特征以及基于这些肽特征的实验建立的测定条件被提供用于大规模特异性 - 基于选择反应监测（SRM）测定，以便直接在从福尔马林固定的癌症患者组织样品获得的蛋白质制剂中测量c-Src的相对或绝对定量水平。